Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Solid Tumors 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Non-small Cell Lung Cancers 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 34Cisplatin 12Nivolumab 10atezolizumab 9Docetaxel 9Carboplatin 9Paclitaxel 8Cetuximab 8Gemcitabine 7Blood Specimen Collection 7Radiotherapy 6Fluorouracil 6Drug Therapy 6cemiplimab 5Pemetrexed 5Immune Checkpoint Inhibitors 5fludarabine 4Standard of Care 4Cyclophosphamide 4spartalizumab 3epacadostat 3Surveys and Questionnaires 3Oncolytic Virotherapy 3Nicotine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Interleukin-2 3Filgrastim 3Bupropion 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × amivantamab × Thoracic × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡